- 专利标题： Fused pyrazine derivatives as A2A / A2B inhibitors
-
申请号： US16502826申请日： 2019-07-03
-
公开(公告)号： US11161850B2公开(公告)日： 2021-11-02
- 发明人: Xiaozhao Wang , Yong Li , Chao Qi , Liangxing Wu , Wenqing Yao , Wenyu Zhu
- 申请人： Incyte Corporation
- 申请人地址： US DE Wilmington
- 专利权人： Incyte Corporation
- 当前专利权人： Incyte Corporation
- 当前专利权人地址： US DE Wilmington
- 代理机构： Fish & Richardson P.C.
- 主分类号： A61P9/00
- IPC分类号： A61P9/00 ; A61P25/28 ; A61P35/00 ; A61P29/00 ; C07D519/00 ; C07D487/04
摘要：
This application relates to compounds of Formula (I): or pharmaceutically acceptable salts thereof, which modulate the activity of adenosine receptors, such as subtypes A2A and A2B receptors, and are useful in the treatment of diseases related to the activity of adenosine receptors including, for example, cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases.
公开/授权文献
- US20200031835A1 FUSED PYRAZINE DERIVATIVES AS A2A / A2B INHIBITORS 公开/授权日：2020-01-30
信息查询
